Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06208514 · ClinicalTrials.gov registry record · NA
Brief Pain Exposure Therapy (BPET) For Nociplastic Pain
A NA study of Fibromyalgia and Lupus Erythematosus, Systemic, sponsored by University of Michigan.
- Recruiting
- Registry status
- NA
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT06208514: Recruiting NA study of Fibromyalgia and Lupus Erythematosus, Systemic, sponsored by University of Michigan.
NCT06208514 is a NA study of Fibromyalgia and Lupus Erythematosus, Systemic that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 125 participants, below the 178-participant average among 76 other Fibromyalgia trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06208514, a NA study of Fibromyalgia and Lupus Erythematosus, Systemic, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- NA
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is intended to test whether a brief Zoom-based behavioral treatment can help adults with fibromyalgia (FM), Lupus, chronic pelvic pain, and chronic low back pain learn effective strategies for reducing pain, disability and other problems that can come with fibromyalgia, Lupus, chronic pelvic pain, and chronic low back pain (such as depression or anxiety).
Primary Outcome
This is a one item scale that participants answer worst pain experienced from no pain (0) to worst pain imaginable (10).
Conditions Studied
Interventions
- BEHAVIORAL Brief pain exposure therapy (BPET)
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-03-04 |
| Est. Completion | 2026-07 |
| Phase | NA |
What NCT06208514 shows while recruiting
NCT06208514 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 178-participant average among 76 other Fibromyalgia trials with a reported enrollment target (30% lower).
The record links to 4 conditions, with Fibromyalgia appearing as the primary indexed condition, and to 1 intervention - of which Brief pain exposure therapy (BPET) is the first listed.
NCT06208514 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06208514 about?
NCT06208514 is a clinical study titled "Brief Pain Exposure Therapy (BPET) For Nociplastic Pain". This study is intended to test whether a brief Zoom-based behavioral treatment can help adults with fibromyalgia (FM), Lupus, chronic pelvic pain, and chronic low back pain learn effective strategies for reducing pain, disability and other problems that can come with fibromyalgia, Lupus, chronic pel...
What is the current status of trial NCT06208514?
This trial is currently recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2024-03-04. Estimated completion is 2026-07.
What conditions does trial NCT06208514 study?
This clinical trial studies the following conditions: Fibromyalgia, Lupus Erythematosus, Systemic, Chronic Low Back Pain (CLBP), Chronic Pelvic Pain.
What interventions are being tested in trial NCT06208514?
The interventions under investigation include: Brief pain exposure therapy (BPET) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06208514?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06208514 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06208514's enrollment target sits among peer trials
125 24th of 76 higher than 53 of 76 other Fibromyalgia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Auricular Neuromodulation in Veterans With Fibromyalgia
RECRUITING · NA
-
Effects of Breathing and Attention Training (BAT) on Pain Modulation
RECRUITING · NA
-
Neural Mechanisms of Light Driven Analgesia
RECRUITING · NA
-
Fibromyalgia Sleep A to ZZZ Study
RECRUITING · NA
-
Explosive Synchronization of Brain Network Activity in Chronic Pain
RECRUITING · NA
-
The Effects of Energy Healing in Fibromyalgia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI